Frontiers in Immunology (Dec 2021)

Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine

  • Rebecca J. Loomis,
  • Anthony T. DiPiazza,
  • Samantha Falcone,
  • Tracy J. Ruckwardt,
  • Kaitlyn M. Morabito,
  • Olubukola M. Abiona,
  • Lauren A. Chang,
  • Ria T. Caringal,
  • Vladimir Presnyak,
  • Elisabeth Narayanan,
  • Yaroslav Tsybovsky,
  • Deepika Nair,
  • Geoffrey B. Hutchinson,
  • Guillaume B. E. Stewart-Jones,
  • Lisa A. Kueltzo,
  • Sunny Himansu,
  • John R. Mascola,
  • Andrea Carfi,
  • Barney S. Graham

DOI
https://doi.org/10.3389/fimmu.2021.772864
Journal volume & issue
Vol. 12

Abstract

Read online

Nipah virus (NiV) represents a significant pandemic threat with zoonotic transmission from bats-to-humans with almost annual regional outbreaks characterized by documented human-to-human transmission and high fatality rates. Currently, no vaccine against NiV has been approved. Structure-based design and protein engineering principles were applied to stabilize the fusion (F) protein in its prefusion trimeric conformation (pre-F) to improve expression and increase immunogenicity. We covalently linked the stabilized pre-F through trimerization domains at the C-terminus to three attachment protein (G) monomers, forming a chimeric design. These studies detailed here focus on mRNA delivery of NiV immunogens in mice, assessment of mRNA immunogen-specific design elements and their effects on humoral and cellular immunogenicity. The pre-F/G chimera elicited a strong neutralizing antibody response and a superior NiV-specific Tfh and other effector T cell response compared to G alone across both the mRNA and protein platforms. These findings enabled final candidate selection of pre-F/G Fd for clinical development.

Keywords